Consequently, these findings suggest that inhibition of FTH1, possibly through the use of DFX or similar agents, could be a viable strategy to potentiate therapeutic outcomes in pancreatic cancer. The gene discussed is FTH1; the disease is familial pancreatic carcinoma.